Evidence map›Paper›PMID 26460262›Full record

ArticleBlood cells, molecules & diseases2015

Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia.

Vladan P Čokić, Slavko Mojsilović, Aleksandra Jauković, Nada Kraguljac-Kurtović, Sonja Mojsilović, Dijana Šefer, Olivera Mitrović Ajtić, Violeta Milošević, Andrija Bogdanović, Dragoslava Đikić and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cells, molecules & diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Vladan P ČokićInstitute for Medical Research, University of Belgrade, Belgrade, Serbia. Electronic address: vl@imi.bg.ac.rs.
Slavko MojsilovićInstitute for Medical Research, University of Belgrade, Belgrade, Serbia.
Aleksandra JaukovićInstitute for Medical Research, University of Belgrade, Belgrade, Serbia.
Nada Kraguljac-KurtovićClinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia.
Sonja MojsilovićInstitute for Medical Research, University of Belgrade, Belgrade, Serbia.
Dijana ŠeferClinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia.
Olivera Mitrović AjtićInstitute for Medical Research, University of Belgrade, Belgrade, Serbia.
Violeta MiloševićClinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia.
Andrija BogdanovićClinic of Hematology, Clinical Center of Serbia, Belgrade, Serbia; Medical Faculty, University of Belgrade, Belgrade, Serbia.
Dragoslava ĐikićInstitute for Medical Research, University of Belgrade, Belgrade, Serbia.
Pavle MilenkovićInstitute for Medical Research, University of Belgrade, Belgrade, Serbia.
Raj K PuriTumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA.
University of Belgrade · RSCentar za Promociju Nauke · RSCenter for Biologics Evaluation and Research · US

Funding

Pharmacological Control Of Human Hemoglobin Gene ExpressionZIADK025016 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI SCHECHTER, ALAN · 2009 to 2025
$2.5M
TRANS-ACTING FACTOR(S) CONTROLLING GLOBIN GENE EXPRESSION IN K562 CELLS &MICEZ01DK025016 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI SCHECHTER, ALAN N. · 1986 to 2008
$277k
Intramural NIH HHS Z01 DK025016NIDDK NIH HHS Z01DK025016-33
6 · The paper itself

Abstract

purposeWe compared the gene expression profile of peripheral blood CD34(+) cells and granulocytes in subjects with chronic myeloid leukemia (CML), with the accent on signaling pathways affected by BCR-ABL oncogene.

methodsThe microarray analyses have been performed in circulating CD34(+) cells and granulocytes from peripheral blood of 7 subjects with CML and 7 healthy donors. All studied BCR-ABL positive CML patients were in chronic phase, with a mean value of 2012±SD of CD34(+)cells/μl in peripheral blood.

resultsThe gene expression profile was more prominent in CML CD34(+) cells (3553 genes) compared to granulocytes (2701 genes). The 41 and 39 genes were significantly upregulated in CML CD34(+) cells (HINT1, TXN, SERBP1) and granulocytes, respectively. BCR-ABL oncogene activated PI3K/AKT and MAPK signaling through significant upregulation of PTPN11, CDK4/6, and MYC and reduction of E2F1, KRAS, and NFKBIA gene expression in CD34(+) cells. Among genes linked to the inhibition of cellular proliferation by BCR-ABL inhibitor Imatinib, the FOS and STAT1 demonstrated significantly decreased expression in CML.

conclusionThe presence of BCR-ABL fusion gene doubled the expression quantity of genes involved in the regulation of cell cycle, proliferation and apoptosis of CD34(+) cells. These results determined the modified genes in PI3K/AKT and MAPK signaling of CML subjects.

Indexed as

Gene Expression Regulation, LeukemicTranscriptomeAntigens, CD34BiomarkersCase-Control StudiesCluster AnalysisFusion Proteins, bcr-ablGene Expression ProfilingGranulocytesHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNeoplastic Stem CellsSignal TransductionAntigens, CD34BiomarkersFusion Proteins, bcr-ablCD34(+) cellsChronic myeloid leukemiaGranulocytesMicroarray analysis

Identifiers

PMID26460262
PMCPMC4607933
OpenAlexW1158287766

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.